Ab Science

Claire Schalon

Alain Moussy

Abdellah Benjahad

Willy Picoul

Didier Pez

Franck Sandrinelli

Jason Martin

Emmanuel Chevenier

The present invention is concerned with substituted oxazole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, autoimmune, allergic, hematological, inflammatory and degenerative disorders. In particular, the compounds of the invention are Syk inhibitors. The invention also relates to a process for manufacturing the compounds of the invention.

Oxazole derivatives that inhibit Syk

Disclosed are compounds of formula I or pharmaceutically acceptable salts thereof: Wherein n, R, R, R, R, R, A, Q and X are as defined in the description. These compounds selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective native and/or mutant c-kit inhibitors.

Benzimidazole derivatives as selective proteine kinase inhibitors

The present invention is concerned with substituted oxazole derivatives that selectively modulate, regulate, and/or inhibit signal transduction mediated by certain native and/or mutant protein kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, autoimmune, allergic, and degenerative disorders. In particular, the presently disclosed compounds are Syk inhibitors.

Diazaspiroalkaneone-substituted oxazole derivatives as spleen tyrosine kinase inhibitors

Growing community of inventors

Gif-sur-Yvette, France

Claire Schalon